Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.70268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Audrey Lasek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Saint Vincent de Paul Hospital, Lille, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals Inc.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Dupilumab, a human monoclonal anti‐interleukin‐4/13 antibody, is approved for treating severe atopic dermatitis (AD) in children aged 6 months–5 years. It received approval for an Early Access Program (EAP) for children by the French Health Authority in October 2022.
Objective
This EAP aims to evaluate the effectiveness and safety of dupilumab in children (aged 6 months–5 years) with severe AD requiring systemic treatment.
Methods
Cumulative data from the French EAP were analysed. Children with severe AD were administered dupilumab 200 and 300 mg (children ≥5 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Saint Vincent de Paul Hospital, Lille, France.
- Dermatology Department, Necker Enfants-Malades Hospital, Paris, France.
- Dermatology Department, La Timone Hospital (AP-HM), Aix Marseille University, Marseille, France.
- Dermatology Department, Nantes University, Nantes, France.
- IVIDATA Life Sciences for Statistics on Behalf of Sanofi, Gentilly, France.
- Medical Affairs Sanofi, Gentilly, France.
ORCID-Profile: Audrey Lasek, Nathalia Bellon, Hélène Aubert, Sébastien Barbarot
Förderung
- Sanofi
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Lasek, A., Bellon, N., Mallet, S., Aubert, H., Vera, C., Achour, L., Thénié, C., Prescilla, R., Abasq-Thomas, C., & Barbarot, S. (2025). Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70268
Vancouver
Lasek A, Bellon N, Mallet S, Aubert H, Vera C, Achour L, et al. Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.70268
BibTeX
@article{Lasek2025,
author = {Lasek, Audrey and Bellon, Nathalia and Mallet, Stéphanie and Aubert, Hélène and Vera, Carine and Achour, Lamia and Thénié, Claire and Prescilla, Randy and Abasq-Thomas, Claire and Barbarot, Sébastien},
title = {Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.70268}
}
EUVIMED